Teva Pharmaceutical Industries (NYSE:TEVA) had its target price boosted by equities researchers at BTIG Research to $20.00 in a report released on Friday. BTIG Research’s price target would suggest a potential upside of 7.47% from the company’s current price.

A number of other research analysts have also issued reports on the stock. TheStreet lowered shares of Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. Credit Suisse Group reiterated an “underperform” rating and issued a $8.00 price objective (down previously from $14.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, November 6th. Royal Bank of Canada set a $11.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “sell” rating in a research note on Wednesday, November 29th. Goldman Sachs Group reiterated a “neutral” rating and issued a $21.00 price objective (down previously from $28.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 31st. Finally, Susquehanna Bancshares cut their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $14.00 and set a “positive” rating on the stock in a research note on Monday, November 6th. Five equities research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $20.65.

Teva Pharmaceutical Industries (NYSE TEVA) opened at $18.61 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $38.31. The stock has a market cap of $17,576.80, a P/E ratio of 4.00 and a beta of 0.55.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. San Francisco Sentry Investment Group CA purchased a new stake in Teva Pharmaceutical Industries during the second quarter worth $106,000. Bronfman E.L. Rothschild L.P. boosted its holdings in Teva Pharmaceutical Industries by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after buying an additional 94 shares in the last quarter. Penserra Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries during the third quarter worth $129,000. Shelter Mutual Insurance Co purchased a new stake in Teva Pharmaceutical Industries during the second quarter worth $133,000. Finally, Fieldpoint Private Securities LLC purchased a new stake in Teva Pharmaceutical Industries during the third quarter worth $171,000. 52.05% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/btig-research-increases-teva-pharmaceutical-industries-teva-price-target-to-20-00/1769303.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.